Effect of Food on Opicapone

Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects

NCT03116308•Bial - Portela C S.A.

Summary

The purpose of this study is to investigate the effect of food on the catechol-O-Methyltransferase (COMT) activity after repeated doses of opicapone (OPC, development code BIA 9-1067) in healthy subjects and to characterize the effects of food on the pharmacokinetics (PK) and tolerability of OPC after repeated doses.

Detailed Description

Single-centre, open-label, single-arm study in 28 healthy subjects. Subjects received a single-dose of 50 mg OPC once-daily (QD) in the evening for 12 days. On Day 1 (D1), 50 mg OPC was orally administered in the evening (reference hour for all other administrations) after a minimum of 6 hours fast. From D2 to D8 subjects were in ambulatory and received 50 mg OPC once-daily (evening administration after 2 hours fast). On D9, 50 mg OPC was orally administered in the evening after a minimum of 6 hours fast. On D10, 50 mg OPC was orally administered in the evening, thirty minutes after the start of a moderate meal (with a previous 6 hours fast). On D11 and D12 subjects received the last doses of 50 mg OPC (evening administration after 2 hours fast).

Eligibility

Age

18 - 45 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Able and willing to give written informed consent and to comply with the study restrictions.
•Male or female subjects aged between 18 and 45 years, inclusive.
•Body mass index (BMI) between 19 and 30 kg/m2, inclusive.
•Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.
•Negative tests for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab at screening.
•Clinical laboratory test results clinically acceptable at screening and admission.
•Negative screen for alcohol and drugs of abuse at screening and admission.
•Non-smokers or ex-smokers for at least 3 months.
•If female:
•Not of childbearing potential by reason of surgery or, if of childbearing potential, she uses an effective non-hormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \[diaphragm or cervical or vault caps\] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he is the sole partner of that subject) for all the duration of the study.
+1 more criteria

Exclusion Criteria

•Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
•Clinically relevant surgical history.
•Clinically relevant abnormality in the coagulation tests.
•Clinically relevant abnormality in the liver function tests.
•History of relevant atopy or drug hypersensitivity, particularly to any COMT inhibitor.
•History of alcoholism or drug abuse.
•Consume more than 14 units of alcohol a week.
•Significant infection or known inflammatory process at screening or admission.
•Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission.
•Used medicines within 2 weeks of admission that may affect the safety or other study assessments, in the investigator's opinion.
+10 more criteria

Key Dates

Start Date

November 21, 2014

Primary Completion Date

January 28, 2015

Completion Date

January 28, 2015

Last Updated

April 17, 2017

Enrollment

ACTUAL participants

Conditions

Parkinson Disease

Interventions

Opicapone (OPC)

DRUG

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Food on Opicapone

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations